
    
      This will be an open-label extension study. All enrolled subjects will be provided with
      udenafil for the duration of the study. Subjects completing the Phase III FUEL study will be
      eligible for recruitment. Additional subjects will be recruited as needed to ensure a minimum
      of 300 total subjects enroll. Safety, pharmacodynamic and quality of life data will be
      collected and analyzed.
    
  